Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A cost-utility analysis of interferon beta for multiple sclerosis.

× No keyword cloud information.

20 in total

1. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.

Authors: J Bryant; A Clegg; R Milne
Journal: BMJ Date: 2000-05-27

2. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

Authors: Tom Walley
Journal: CNS Drugs Date: 2004 Impact factor: 5.749

3. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors: R B Forbes; A Lees; N Waugh; R J Swingler
Journal: BMJ Date: 1999-12-11

4. Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.

Authors: Trudy Owens; Nikos Evangelou; David K Whynes
Journal: Eur J Health Econ Date: 2012-01-24

5. Multiple sclerosis in the UK: service use, costs, quality of life and disability.

Authors: Paul McCrone; Margaret Heslin; Martin Knapp; Paul Bull; Alan Thompson
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

6. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors: Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

Review 7. Early intervention in multiple sclerosis : better outcomes for patients and society?

Authors: Peter Flachenecker; Peter Rieckmann
Journal: Drugs Date: 2003 Impact factor: 9.546

Review 8. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors: Ceri J Phillips
Journal: CNS Drugs Date: 2004 Impact factor: 5.749

Review 9. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

Authors: Paul L McCormack; Lesley J Scott
Journal: CNS Drugs Date: 2004 Impact factor: 5.749

10. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors: Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal: Clin Drug Investig Date: 2004 Impact factor: 2.859